Cyclerion Therapeutics, Inc. (CYCN) is a clinical-stage biopharmaceutical company that focuses on harnessing the potential of soluble guanylate cyclase (sGC) pharmacology in order to treat a range of serious and orphan diseases. The company was established in 2018 as a spin-off from Ironwood Pharmaceuticals. It is based in Cambridge, Massachusetts, which is a well known hub for biotech innovation.
The mission of Cyclerion Therapeutics is to develop breakthrough treatments for serious and life-threatening diseases by discovering, developing, and commercializing novel, first-in-class therapies that target sGC. The company's vision is to find, create, and commercialize innovative medicines that have the potential to transform the lives of those affected by serious diseases.
Cyclerion has a diverse portfolio of pivotal and mid-stage clinical research programs. These programs are driven by the company's proprietary design platform, which enables it to develop pharmaceutical compounds that target the diverse range of tissues influenced by sGC biology. Moreover, Cyclerion has established collaborations with several leading academic centers of excellence to further its understanding of sGC pharmacology and its role in various diseases.
One of the most advanced drug candidates in Cyclerion's pipeline is praliciguat, which is being developed for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF). Praliciguat is a once-daily, orally available sGC stimulator. Another notable candidate is olinciguat, an oral sGC stimulator for patients with sickle cell disease. It is currently in Phase 2 clinical trials.
With the focus on treating serious diseases, Cyclerion is also dedicated to its corporate and social responsibilities. The company aims at improving patient care and health outcomes, promoting ethical practices in medicine and research, and engaging with stakeholders to ensure sustainability.
Cyclerion’s team is made up of dedicated scientists, clinical development professionals, and business leaders who have extensive experience in medical affairs, business development, finance and operations. They are united by a common purpose - the desire to transform the lives of patients with serious diseases.
Despite several challenges faced by Cyclerion including clinical setbacks and changes in leadership, the company has shown resilience and commitment towards achieving its mission.
In summary, Cyclerion Therapeutics Inc. (CYCN) is a pioneering biotechnology company which works on harnessing the power of sGC pharmacology for the treatment of serious and orphan diseases. With a clear strategic focus, a passion for science, and a commitment to improve patient lives, Cyclerion is poised to make significant contributions to the field of medicine.